Raloxifene, originally developed to treat osteoporosis and prevent breast cancer, is a selective (o)estrogen receptor modulator (SERM), raloxifene offers a non-invasive option for mitigating breast tissue growth and alleviating dysphoria associated with breast development.
Mitigating Breast Tissue Growth
Raloxifene works by selectively binding to oestrogen receptors in breast tissue, thereby inhibiting the effects of oestrogen on cell proliferation and growth. By blocking oestrogen's stimulatory effects, raloxifene can help prevent further breast tissue development in transgender women and non-binary individuals undergoing hormone therapy, promoting a reduction in breast size and alleviating discomfort or dysphoria.
Non-Invasive Alternative
One of the notable advantages of raloxifene is its non-invasive nature compared to surgical breast reduction procedures. As an oral medication taken daily, raloxifene offers a convenient and accessible option for individuals seeking to reduce breast size without undergoing surgery. This approach may be particularly appealing for those who prefer to avoid surgical interventions or who are not surgical candidates.
Adjunct to Hormone Therapy
Raloxifene serves as a valuable adjunct to hormone therapy by targeting specific areas for breast reduction, such as the breast tissue itself. While oestrogen therapy promotes overall feminization, including breast development, raloxifene can help counteract this effect by modulating oestrogen receptor activity, leading to a reduction in breast size and improved chest contour.